Literature DB >> 23751994

Experience with stent implantation in malignant esophageal strictures: analysis of 1185 consecutive cases.

Akos Balazs1, Peter Kokas, Peter Lukovich, Peter K Kupcsulik.   

Abstract

PURPOSE: The aim of this retrospective study was to analyze the experience in endoprosthesis implantation in cases of malignant esophageal strictures.
METHODS: A total of 1185 consecutive patients underwent endoprosthesis implantation: through open surgery in 42 cases and by endoscopy in 1143 cases.
RESULTS: Stent implantation was performed successfully in 61.2% of cases. Dysphagia was resolved temporarily in 6.2% and permanently in 93.5% of cases. The score of dysphagia decreased from 1.93 to 0.38. Complications were detected in 23.7% of patients, and 69.2% of cases were treated by endoscopy. Wound complications were seen in 21.9% of patients intubated through surgery. The mean survival time of patients with esophageal intubation was 5.4 months and that of patients not eligible for stent implantation was 3.3 months.
CONCLUSIONS: Stent implantation improves the quality of life and gives an opportunity for adjuvant oncological therapy. Evaluation of morphologic anomalies is of considerable importance for achieving success in treatment through implantation.

Entities:  

Mesh:

Year:  2013        PMID: 23751994     DOI: 10.1097/SLE.0b013e31828ba120

Source DB:  PubMed          Journal:  Surg Laparosc Endosc Percutan Tech        ISSN: 1530-4515            Impact factor:   1.719


  2 in total

1.  Stent type used does not impact complication rate or placement time but can decrease treatment cost for benign and malignant esophageal lesions.

Authors:  Camille McGaw; Ahmad Alkaddour; Kenneth J Vega; Juan Carlos Munoz
Journal:  World J Gastrointest Endosc       Date:  2016-04-10

2.  Complications after treating esophageal strictures with prostheses and stents - 20 years' experience.

Authors:  Mariusz P Łochowski; Daniel Brzeziński; Marek Rębowski; Józef Kozak
Journal:  Wideochir Inne Tech Maloinwazyjne       Date:  2016-12-29       Impact factor: 1.195

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.